Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-08-31 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2023-08-31 English
20-F
Annual Report FY 2023
2023-08-31 English
Preliminary Final Report including Appendix 4E 255 pages 3.5MB
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the United States SEC for the fiscal year ended June 30, 2023, by Mesoblast Limited. It is explicitly labeled as an "Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934." The Form 20-F is the annual report filed by foreign private issuers and contains comprehensive financial statements, management discussion, and other detailed disclosures. The document includes a detailed table of contents referencing financial statements, management discussion, corporate governance, and other annual report components. The length of the document (15,000 characters) and the presence of substantive financial and operational information confirm it is the full annual report, not just an announcement or certification. Therefore, the correct classification is Annual Report (10-K equivalent for foreign issuers).
2023-08-30 English
Annual Financial Results Presentation 28 pages 1.8MB
Annual Report Classification · 95% confidence The document is a detailed financial results and operational update presentation for the year ended June 30, 2023, by Mesoblast. It includes comprehensive financial highlights, operational updates, regulatory status, clinical pipeline information, and strategic plans. The presence of detailed financial data such as revenue, expenses, cash reserves, and loss before tax, along with operational and regulatory updates, indicates this is a full annual financial report rather than a brief earnings release or a simple announcement. The document is about 15,000 characters long, which supports it being a full report. It is not a transcript, proxy statement, or a regulatory filing of a different nature. Therefore, the document fits the definition of an Annual Report (10-K equivalent).
2023-08-30 English
MSB Annual Financial Results and Operational Update 7 pages 560.7KB
Annual Report Classification · 95% confidence The document is a detailed financial and operational update for the fiscal year ended June 30, 2023, including comprehensive financial results, cash reserves, revenues, expenses, and management commentary. It also discusses strategic updates, cost containment plans, and clinical trial progress. The presence of full financial data, management discussion, and operational details indicates this is a comprehensive financial report rather than a brief announcement or a transcript. The document is not a short announcement or a certification but a full report of the company's annual financial performance and operational status. Therefore, it fits the definition of an Annual Report (10-K).
2023-08-30 English
Change in substantial holding 6 pages 1.0MB
Regulatory Filings Classification · 90% confidence The document contains only references to omitted pictures and no textual content or financial data. It is extremely short (165 characters) and does not contain any report, announcement, or detailed information. Given the lack of content, it does not fit any specific report category and should be classified as a Regulatory Filing (RNS) as a fallback category.
2023-08-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.